Prior Authorization Form

Note: Please provide as much information as possible on this form. Missing data may cause processing delays for requested authorization(s). Attach additional sheets to this form if necessary.

Please fax the completed PA form and any additional informational sheets to Nirvanahealth at the following fax number: +1(866) 871-8565

Patient Information		Prescriber Information	
Patient Name:		Prescriber Name:	
Health Plan Name:		Prescriber Address:	
Patient Insurance Id:			
Patient Date of Birth:		Prescriber Phone:	( )
Patient Phone:		Prescriber Fax:	( )
		Prescriber Specialty:	
		Prescriber DEA:	
		Prescriber NPI:	

Medication & Medical Information	
Requested Drug(s) & Strength(s):	[ ] Lenvima 10 mg/day (10 mg x 1) capsule [ ] Lenvima 12 mg/day (4 mg x 3) capsule [ ] Lenvima 14 mg/day(10 mg x 1-4 mg x 1) capsule [ ] Lenvima 18 mg/day (10 mg x 1 and 4 mg x 2) capsule [ ] Lenvima 20 mg/day (10 mg x 2) capsule [ ] Lenvima 24 mg per day (10 mg x 2 and 4 mg x 1) capsule [ ] Lenvima 4 mg capsule [ ] Lenvima 8 mg/day (4 mg x 2) capsule
Requested Daily Quantity Limit – Amount:	
Requested Daily Quantity Limit – Days:	
Requested Quantity Limit Over Time – Amount:	
Requested Quantity Limit Over Time – Days:	
Requested Quantity Per Rx – Amount:	
Expected Length of Therapy:	
Directions:	
Diagnosis and Diagnosis Codes (ICD-10 Standard Codes):	
List drugs used previously to treat the same condition:	
Additional clinical information or history. Please include any relevant test results and/or medical record notes:	

Questionnaire

Q1: I, as the provider or designated representative of the provider, certify and attest that the information provided is complete and accurate and that, upon request, I shall provide any information to RxAdvance that RxAdvance determines is reasonably necessary to verify my responses. (Check only one that apply)

[ ] Yes

[ ] No

Q2: Is the member currently treated with this medication? (Check only one that apply)

[ ] Yes (please list start date of therapy (month/day/year)) _____ (*Required)

[ ] No

Q3: What is the member's diagnosis? (Check only one that apply)

[ ] Locally recurrent or metastatic differentiated thyroid cancer (DTC) (please specify the type of DTC) _____(*Required)

[ ] Advanced renal cell carcinoma (RCC)

[ ] Hepatocellular Carcinoma (HCC)

[ ] Endometrial Carcinoma (EC)

[ ] Other (please specify the member's diagnosis and provide clinical rationale for the request) _____(*Required)

Q4: What is the member's diagnosis? (Check only one that apply)

[ ] Locally recurrent or metastatic differentiated thyroid cancer (DTC) (please specify the type of DTC) _____(*Required)

[ ] Advanced renal cell carcinoma (RCC)

[ ] Hepatocellular Carcinoma (HCC)

[ ] Endometrial Carcinoma (EC)

[ ] Other (please specify the member's diagnosis and provide clinical rationale for the request) _____(*Required)

Q5: Does the member have symptomatic or progressive disease? (Check only one that apply)

[ ] Yes

[ ] No (please provide clinical rationale for the request) _____ (*Required)

Q6: Is the disease refractory to radioactive iodine treatment? (Check only one that apply)

[ ] Yes

[ ] No (please provide clinical rationale for the request) _____ (*Required)

Q7: Is the requested medication used as first-line treatment? (Check only one that apply)

[ ] Yes

[ ] No

Q8: Is the medication used in combination with Keytruda (pembrolizumab)? (Check only one that apply)

[ ] Yes

[ ] No

Q9: Will member's drug treatment follow one prior anti-angiogenic therapy? (Check only one that apply)

[ ] Yes

[ ] No (please provide clinical rationale for the request) _____ (*Required)

Q10: Is the requested medication used in combination with everolimus? (Check only one that apply)

[ ] Yes

[ ] No (please provide clinical rationale for the request) _____ (*Required)

Q11: Does the member have metastatic disease? (Check only one that apply)

[ ] Yes

[ ] No

Q12: Does the member have extensive liver tumor burden? (Check only one that apply)

[ ] Yes

[ ] No

Q13: Is the member inoperable by performance status or comorbidity (local disease or local disease with minimal extrahepatic disease only)? (Check only one that apply)

[ ] Yes

[ ] No

Q14: Does the member have unresectable disease? (Check only one that apply)

[ ] Yes

[ ] No (please provide clinical rationale for the request) _____ (*Required)

Q15: Is the endometrial carcinoma microsatellite instability-high (MSI-H)? (Check only one that apply)

[ ] Yes

[ ] No

Q16: Is the endometrial carcinoma mismatch repair deficient (dMMR)? (Check only one that apply)

[ ] Yes

[ ] No (please provide clinical rationale for the request)

Q17: Does the member have disease progression after following systemic therapy? (Check only one that apply)

[ ] Yes (please specify drug names and the start and end date(s) of therapy (month/year))
_____(*Required)

[ ] No (please provide clinical rationale for the request) _____ (*Required)

Q18: Is the medication used in combination with Keytruda (pembrolizumab)? (Check only one that apply)

[ ] Yes

[ ] No (please provide clinical rationale for the request) _____ (*Required)

Q19: Is the member a candidate for curative surgery or radiation therapy? (Check only one that apply)

[ ] Yes (please provide clinical rationale for the request)

[ ] No

Q20: Is the requested drug prescribed by or in consultation with a oncologist, hepatologist, or gastroenterologist? (Check only one that apply)

[ ] Yes (please provide prescriber specialty) _____(*Required)

[ ] No (please provide clinical rationale for the request) _____ (*Required)

Q21: Is the requested drug prescribed by or in consultation with a oncologist? (Check only one that apply)

[ ] Yes

[ ] No (please provide clinical rationale for the request) _____ (*Required)

Attestation: I attest the information provided is true and accurate to the best of my knowledge. I understand that the Health Plan, Insurer, Medical Group or its designated representatives may perform a routine audit and request the medical information necessary to verify the accuracy of the information reported on this form.	
Signature of Prescriber or Authorized Representative:	Date:
Print Authorized Representative Name:	